GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Biolase Inc (NAS:BIOL) » Definitions » EBIT

Biolase (Biolase) EBIT : $-18.24 Mil (TTM As of Dec. 2023)


View and export this data going back to 1992. Start your Free Trial

What is Biolase EBIT?

Biolase's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2023 was $-4.74 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2023 was $-18.24 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Biolase's annualized ROC % for the quarter that ended in Dec. 2023 was -113.25%. Biolase's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -185.20%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Biolase's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -112.13%.


Biolase EBIT Historical Data

The historical data trend for Biolase's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biolase EBIT Chart

Biolase Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -15.74 -14.34 -13.87 -25.78 -18.24

Biolase Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -8.31 -5.27 -4.25 -3.98 -4.74

Competitive Comparison of Biolase's EBIT

For the Medical Devices subindustry, Biolase's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biolase's EV-to-EBIT Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Biolase's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Biolase's EV-to-EBIT falls into.



Biolase EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-18.24 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biolase  (NAS:BIOL) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Biolase's annualized ROC % for the quarter that ended in Dec. 2023 is calculated as:

ROC % (Q: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2023 ) + Invested Capital (Q: Dec. 2023 ))/ count )
=-20.304 * ( 1 - 0.28% )/( (18.551 + 17.206)/ 2 )
=-20.2471488/17.8785
=-113.25 %

where

Note: The Operating Income data used here is four times the quarterly (Dec. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Biolase's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2023  Q: Dec. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-18.952/( ( (7.767 + max(3.868, 0)) + (7.044 + max(1.787, 0)) )/ 2 )
=-18.952/( ( 11.635 + 8.831 )/ 2 )
=-18.952/10.233
=-185.20 %

where Working Capital is:

Working Capital(Q: Sep. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(4.388 + 13.824 + 1.761) - (12.385 + 2.191 + 1.529)
=3.868

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(5.483 + 11.433 + 1.381) - (12.695 + 2.452 + 1.363)
=1.787

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Biolase's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2023 )
=-18.239/16.266
=-112.13 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biolase EBIT Related Terms

Thank you for viewing the detailed overview of Biolase's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Biolase (Biolase) Business Description

Traded in Other Exchanges
Address
27042 Towne Centre Drive, Suite 270, Lake Forest, CA, USA, 92610
Biolase Inc is a US-based medical device company. It develops, manufactures, markets, and sells laser systems in dentistry and medicine. The company also markets, sells and distributes dental imaging equipment, including cone beam digital x-rays and CAD/CAM intraoral scanners. It offers two categories of laser system products: Waterlase (all-tissue) systems and Diode (soft-tissue) systems which allow dentists, periodontists, endodontists, oral surgeons, and other dental specialists to perform a broad range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications. The majority of the company's revenue comes from the United States.
Executives
Goldman Sachs & Co. Llc 10 percent owner 200 WEST STREET, NEW YORK NY 10282
Goldman Sachs Group Inc 10 percent owner 200 WEST STREET, NEW YORK NY 10282
Lord Jonathan T Md director 500 WEST MAIN ST., LOUISVILLE KY 40202
Jennifer Bright officer: Chief Financial Officer 27042 TOWNE CENTRE DRIVE,, SUITE 270, FOOTHILL RANCH CA 92610
Steven Sandor officer: Chief Operating Officer 27042 TOWNE CENTRE DRIVE,, SUITE 270, FOOTHILL RANCH CA 92610
Jess Roper director 5555 OBERLIN DRIVE, SAN DIEGO CA 92121
Kenneth P. Yale director 27042 TOWN CENTRE DRIVE, SUITE 270, FOOTHILL RANCH CA 92610
John R Beaver director, officer: President & CEO C/O STERLING CHEMICALS INC, 1200 SMITH STREET, HOUSTON TX 77002
Kathleen T Oloughlin director 27042 TOWN CENTRE DRIVE, SUITE 270, FOOTHILL RANCH CA 92610
Somerman Martha J. Dds, Phd director 27042 TOWN CENTRE DRIVE, SUITE 270, FOOTHILL RANCH CA 92610
Summerhays Carol Gomez Dds director 27042 TOWN CENTRE DRIVE, SUITE 270, FOOTHILL RANCH CA 92610
Family Foundation Schuler 10 percent owner 100 N. FIELD DRIVE, SUITE 360, LAKE FOREST IL 60045
Larry N Feinberg 10 percent owner C/O ORACLE PARTNERS L P, 200 GREENWICH AVENUE, GREENWICH CT 06830
Jack W Schuler 10 percent owner 100 N. FIELD DRIVE, SUITE 360, LAKE FOREST IL 60045
Michael Ditolla director 3299 CAMBRIDGE AVE, BRONX NY 10463